Survodutide
Also Known As: BI 456906, BI-456906, Survodutide peptide, GLP-1 glucagon dual agonist BI 456906, Boehringer dual agonist, GCGR GLP-1R dual agonist, GLP-1 glucagon obesity drug, Survodutide BI456906, Dual incretin glucagon agonist, GLP-1/glucagon dual agonist, survo, dual agonist
Survodutide is a research-grade Synthetic dual agonist: GLP-1 receptor + glucagon receptor targeting GLP-1R studied in Weight Loss & Metabolism research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Investigational - In active human clinical trials; not yet approved.
An investigational dual-agonist weight-loss and liver-disease peptide.
At A Glance
| Category | Weight Loss & Metabolism |
|---|---|
| Compound Class | Synthetic dual agonist: GLP-1 receptor + glucagon receptor |
| Molecular Target | GLP-1R (satiety, insulin secretion) + GCGR (glucagon receptor: energy expenditure, hepatic lipid metabolism); dual incretin-glucagon signaling |
| Molecular Weight | 4231.63 Da |
| Amino Acid Sequence | GLP-1/glucagon dual agonist (acylated synthetic peptide) |
| CAS Number | 2805997-46-8 |
| Half-Life | ~1 week |
| WADA Status | not_listed |
| Evidence Tier | Investigational |
Mechanism Of Action
It is a dual agonist that hits both the GLP-1 receptor (to stop hunger) and the Glucagon receptor (to actively force the liver to burn stored fat and increase energy expenditure).
Studied For
- Obesity / overweight
- Type 2 diabetes
- MASH / metabolic liver disease
- Non-alcoholic steatohepatitis (NASH)
- Liver fat reduction
- Dual GLP-1 glucagon therapy
- HbA1c lowering
- Body weight reduction
- Cardiovascular risk reduction
- Insulin resistance
- Metabolic syndrome
- Hepatic steatosis
- Lipid metabolism
- weight loss
- liver fat reduction
- NASH
- NAFLD
- obesity
- energy expenditure increase
Reported Research Findings
Pooled trial data associate 4 to 11 months of treatment with roughly 7 to 9 percent weight reduction, plus Phase 2 liver-disease activity.
Safety And Handling Notes
Predominantly gastrointestinal; glucagon agonism can raise heart rate.
Investigational with no approved indication or long-term safety data despite positive Phase 3 readouts in 2026; GLP-1 and glucagon class considerations remain under study. Research use only.
Regulatory Status
Investigational (Boehringer Ingelheim / Zealand Pharma); not FDA-approved. Phase 3 SYNCHRONIZE-1 reported positive topline results on 28 April 2026, meeting co-primary endpoints with mean weight loss of up to 16.6% at 76 weeks versus 3.2% for placebo (efficacy estimand). Phase 3 SYNCHRONIZE-MASLD met both primary endpoints, with liver fat normalization in about 6 of 10 treated participants at 48 weeks. Full results were presented at the ADA 2026 Scientific Sessions and published in The New England Journal of Medicine and Nature Medicine. Holds FDA Breakthrough Therapy designation for MASH. Not on the WADA 2026 Prohibited List.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.